Decoy Therapeutics Inc.
NASDAQ Capital MarketTotal Valuation
Decoy Therapeutics Inc. carries a market capitalization of 621,711.00, placing it among publicly traded companies globally.
| Market Cap | 621,711.00 |
| Enterprise Value | N/A |
Share Statistics
Decoy Therapeutics Inc. currently has 531,968.00 shares outstanding.
| Shares Outstanding | 531,968.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.89 |
| P/TBV Ratio | 0.89 |
| P/FCF Ratio | -0.32 |
| P/OCF Ratio | -0.32 |
Financial Position
Decoy Therapeutics Inc. maintains a current ratio of 1.83, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.83 |
| Quick Ratio | 1.77 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -1,139.59 |
| Return on Assets (ROA) | -278.04 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Decoy Therapeutics Inc.'s stock has declined approximately -97.59527% over the past 52 weeks. The 50-day moving average sits at 2.62, while the 200-day moving average is 5.90.
| Beta (5Y) | N/A |
| 52-Week Price Change | -97.59527% |
| 50-Day Moving Average | 2.62 |
| 200-Day Moving Average | 5.90 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -14.59M, while operating income came in at -14.62M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -14.62M |
| Pretax Income | -14.45M |
| Net Income | -14.45M |
| EBITDA | -14.59M |
| EBIT | -14.62M |
| Earnings Per Share (EPS) | -39.25 |
Balance Sheet
Total book value stands at 4.32M, with working capital of 3.89M providing operational flexibility.
| Cash & Cash Equivalents | 8.29M |
| Total Debt | N/A |
| Net Debt | -8.29M |
| Equity (Book Value) | 4.32M |
| Book Value Per Share | 8.12 |
| Working Capital | 3.89M |
Cash Flow
Decoy Therapeutics Inc. produced -8.32M in operating cash flow over the past twelve months.
| Operating Cash Flow | -8.32M |
| Capital Expenditures | N/A |
| Free Cash Flow | -8.32M |
| FCF Per Share | -22.61 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -394.69 |
| FCF Yield | -314.52 |
Stock Splits
Decoy Therapeutics Inc.'s most recent stock split took place on March 9, 2026 with a 12:1 split ratio.
| Last Split Date | 3/9/2026 |
| Split Ratio | 12:1 |
Scores
Decoy Therapeutics Inc. posts an Altman Z-Score of -19.75, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -19.75 |